Welcome to Bionucleon

Bionucleon is a Start-up company, spin-off of CNR of Naples, founded in 2005 with the aim to develop a new technology to improve oligo-based ligands as drugs.

The emergent use of oligo-based ligands against circulanting targets (e.g. aptamers and DNazyme) is an interesting field for pharmaceutical and biotech companies, for this reason Bionucleon has developed a new oliog-based molecular class with improved serum resistance and better pharmacological behaviour. Our expertize and technology allows us to generate with a SELEX–independent method new oligo-based ligands with improved serum resistance, specificity and no toxicity.

We are committed to:

  • Discover new oligo-based ligands against extracellular and membrane protein targets.

  • Improve the pharmacological behavior of oligonucleotidic ligands;

The company is located in the Bioindustry Park in Colleretto Giacosa (Turin) and has a second R&D unit in Naples. Bionucleon Srl is part of the Eporgen Venture Spa group.


Back